Immunocore Cash Flow Statement
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunocore free cash flow
In fiscal 2025, Immunocore generated -$10.7 million of operating cash flow and spent $4.3 million on capital expenditures. That left free cash flow of -$15.1 million, a free-cash-flow margin of -3.8% of revenue. Free cash flow was down 172.1% from the prior year's $20.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Immunocore cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Net Income | -35.51M | -51.09M | -55.29M | -52.54M | -180.03M |
| Net Income growth (YoY) | — | — | — | — | — |
| Depreciation & Amortization | 3.10M | 4.20M | 4.10M | 5.30M | 7.60M |
| Stock-Based Compensation | 37.70M | 34.19M | 32.47M | 32.89M | 48.89M |
| Change in Working Capital | -16.36M | -9.30M | -33.78M | -49.45M | -31.98M |
| Operating Cash Flow | -10.71M | 26.06M | 2.94M | -49.21M | -143.11M |
| Capital Expenditures | -4.34M | -5.17M | -5.42M | -2.20M | -1.39M |
| Investing Cash Flow | -16.34M | -355.13M | -5.42M | -2.20M | -1.28M |
| Financing Cash Flow | 12.37M | 343.88M | 34.35M | 145.44M | 288.19M |
| Net Change in Cash | -14.68M | 14.81M | 31.86M | 94.04M | 143.80M |
| Free Cash Flow | -15.05M | 20.89M | -2.48M | -51.41M | -144.49M |
This table shows 5 annual periods of Immunocore's cash flow statement, from FY 2025 back to FY 2021, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IMCR's reporting calendar. What is a cash flow statement?